A Second Life for MAP, a Model Amphipathic Peptide

Int J Mol Sci. 2022 Jul 28;23(15):8322. doi: 10.3390/ijms23158322.

Abstract

Cell-penetrating peptides (CPP) have been shown to be efficient in the transport of cargoes into the cells, namely siRNA and DNA, proteins and peptides, and in some cases, small therapeutics. These peptides have emerged as a solution to increase drug concentrations in different tissues and various cell types, therefore having a relevant therapeutic relevance which led to clinical trials. One of them, MAP, is a model amphipathic peptide with an α-helical conformation and both hydrophilic and hydrophobic residues in opposite sides of the helix. It is composed of a mixture of alanines, leucines, and lysines (KLALKLALKALKAALKLA). The CPP MAP has the ability to translocate oligonucleotides, peptides and small proteins. However, taking advantage of its unique properties, in recent years innovative concepts were developed, such as in silico studies of modelling with receptors, coupling and repurposing drugs in the central nervous system and oncology, or involving the construction of dual-drug delivery systems using nanoparticles. In addition to designs of MAP-linked vehicles and strategies to achieve highly effective yet less toxic chemotherapy, this review will be focused on unique molecular structure and how it determines its cellular activity, and also intends to address the most recent and frankly motivating issues for the future.

Keywords: CNS; cell-penetrating peptides; delivery system; drug repurposing; model amphipathic peptide; nanoparticles; oncology.

Publication types

  • Review

MeSH terms

  • Cell-Penetrating Peptides* / chemistry
  • Drug Delivery Systems
  • Hydrophobic and Hydrophilic Interactions
  • Oligonucleotides / metabolism
  • RNA, Small Interfering / genetics

Substances

  • Cell-Penetrating Peptides
  • Oligonucleotides
  • RNA, Small Interfering

Grants and funding

This work was financed by FEDER—Fundo Europeu de Desenvolimento Regional through the COMPETE 2020—Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia, in a framework of the projects in CINTESIS, R&D Unit (reference UIDB/4255/2020 and iMed.ULisboa (UID/DTP/04138/2019). This work was also financed by national funds through FCT within the scope of the project “RISE—LA/P/0053/2020. S.S. thanks FCT for supporting this article with her PhD Grant (PD/BD/135456/2017). N.V. also thanks the support from FCT and FEDER (European Union), award number IF/00092/2014/CP1255/CT0004 and CHAIR in Onco-Innovation at FMUP.